Abstract
Anti-phospholipid syndrome (APS) is a systemic autoimmune disease resulting in vascular thrombosis and pregnancy morbidity affecting both mother and foetus. In obstetric APS, the aim of management is ensuring adequate anticoagulation and maternal and foetal well-being through regular monitoring. Perinatal counseling is important to reassure the couple that a good outcome is possible through proper monitoring and regular follow up with both the rheumatology and obstetric teams. In the case of vascular APS, the switch to heparin needs to be done as soon as pregnancy is detected, whereas, in obstetric APS, heparin needs to be started at this time. The dose of heparin is different in the case of vascular APS patients getting pregnant compared to only obstetric APS. Low-dose aspirin is generally added to both regimens. In the post-partum period, heparin is continued till 6 weeks and then discontinued in obstetric APS. In contrast, in vascular APS, reinitiation of vitamin K oral antagonist should be done as this is safe in lactation.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Gerardi MC, Fernandes MA, Tincani A, Andreoli L (2018) Obstetric anti-phospholipid syndrome: state of the art. Curr Rheumatol Rep 20(10):59
Meroni PL, Borghi MO, Grossi C, Chighizola CB, Durigutto P, Tedesco F (2018) Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases? Nat Rev Rheumatol 14(7):433–440
Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4(2):295–306
Garcia D, Doruk E (2018) Diagnosis and management of the antiphospholipid syndrome. N Engl J Med 378(21):2010–2021
Devreese KM, Pierangeli SS, de Laat B, Tripodi A, Atsumi T, Ortel TL, For the Subcommittee on Lupus Anticoagulant/Phospholipid/Dependent Antibodies (2014) Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. J Thromb Haemost 12:792–795
Uthman I, Noureldine MHA, Ruiz-Irastorza G et al (2019) Management of antiphospholipid syndrome. Ann Rheum Dis 78:155–161
Andreoli L, Bertsias GK, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N et al (2017) EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis 76(3):476–485
Sciascia S, Sanna G, Murru V, Roccatello D, Munther A (2013) GAPSS: the global anti-phospholipid syndrome score. Rheumatology (Oxford) 52(8):1397–1403
Schreiber K, Sciascia S, de Groot PG, Devreese K, Jacobsen S, Ruiz-Irastorza G et al (2018) Antiphospholipid syndrome. Nat Rev Dis Primers 4:17103
Antovic A, Sennström M, Bremme K, Svenungsson E (2018) Obstetric antiphospholipid syndrome. Lupus Sci Med 5:e000197
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Chattopadhyay, A., Dhir, V. (2020). Managing APLA During Pregnancy. In: Sharma, S. (eds) Women's Health in Autoimmune Diseases. Springer, Singapore. https://doi.org/10.1007/978-981-15-0114-2_15
Download citation
DOI: https://doi.org/10.1007/978-981-15-0114-2_15
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-15-0113-5
Online ISBN: 978-981-15-0114-2
eBook Packages: MedicineMedicine (R0)